In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds.
The in vitro antifungal activity of FK463 against a variety of clinically important opportunistic molds was compared with amphotericin B, itraconazole and fluconazole by using the broth microdilution method M27-A specified by the National Committee for Clinical Laboratory Standards. FK463 exhibited potent activity against Aspergillus species, which was superior to those of all other compounds tested. FK463 was also active against the dematiaceous fungi Cladosporium trichoides, Exophiala spinifera, Fonsecaea pedrosoi, and Exophiala dermatitidis except for certain clinical isolates. However, FK463 had no activity against Fusarium solani, Pseudallesheria boydii, and the zygomycetes Absidia corymbifera, Cunninghamella elegans, Rhizopus oryzae, and Rhizopus microsporus var. rhizopodiformis. These results suggest that FK463 has potential utility for the treatment for infections caused by Aspergillus species and dematiaceous fungi.
Nakai
T
T
Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, Chiba, Japan. toru_nakai@po.fujisawa.co.jp
Uno
J
J
Otomo
K
K
Ikeda
F
F
Tawara
S
S
Goto
T
T
Nishimura
K
K
Miyaji
M
M
D001230:Aspergillus / Q000187:drug effects* / Q000472:pathogenicity; D054714:Echinocandins; D005658:Fungi / Q000187:drug effects / Q000472:pathogenicity; D055666:Lipopeptides; D008074:Lipoproteins / Q000494:pharmacology*; D000077551:Micafungin; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000494:pharmacology*
D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D000077551:Micafungin